Journal of International Psychiatry

〇bjective To explore the efficacy, acceptability and safety of 5 new - generation antipsychotics(e g. aripiprazole, resperidone, quetiapine, olanzapine, ziprasidone) in treating first - episode schizophrenia. Methods 200 cases of first-episode schizophrenia were recruited and randomly given one of 5 new-generation anti- psychotics respectively when inclusion. Clinical efficacy was assessed by Brief Psychiatric Rating Scale, acceptabili- ty was evaluated mainly by drug combination, change another medication proportion and maintain original drug rate of each antipsychotics, and safety of each anLipsychotics were estimated by its side effects. Results 1. BPRS scores after treatment were all significantly decreased than prior treatment in each of 5 new-generation antipsychotics(all P value<0.01). While BPRS reduction scores of resperidone were markedly higher Lhan thaL of aripiprazole (P< 0.01) and olanzapine (f)<0.05) 2. Acceptability of olanzapine was remarkably better than that of aripiprazole (P =0.027) and ziprasidone (P=0.015) , meanwhile, quetiapine was also markedly better than that of ziprasidone (P=0.037). 3.The difference of EPS, changes of ECG, abnormal liver functions, constipation and leukopenia a- mong5 new-generation antipsychotics were not detected. Conclusion The efficacy of 5 new - generation antipsy- chotics in treating 「irst-episode schizophrenia were all significant, The accepLability of olanzapine and quetiapine were better among5 new-generation antipsychotics, Side effects of 5 new-generation antipsychotics were similar.

First-episode; Sichizophrenia; Antipsychotics; Efficacy; Acceptability and safety